Fig. 6
From: Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy
(A) Schematic illustration of PBNPs-based photothermal therapy combined with checkpoint (CTLA-4) inhibition for photothermal immunotherapy of neuroblastoma. (B) Normalized tumor growth curves and Kaplan-Meier survival plots of neuroblastoma mice receiving photothermal immunotherapy and the other groups (log-rank test; p < 0.05); (n ≥ 5/group). X) Tumor growth curves and higher long-term survival in the rechallenged group compared to naïve mice (log-rank test, p < 0.05); (n ≥ 3/group). Copyright 2017 [163], Elsevier Ltd. D) αCD137-PBNPs synthesis scheme, treatment regimen and proposed mechanism of action of αCD137-PBNPs-PTT to trigger anti-tumor immunity in SM1 melanoma. E) Kaplan-Meier survival curve of all mice in this experiment. F) Serum AST and ALT activity reveals no increased hepatoxicity in αCD137-PBNP-PTT-treated versus control and untreated SM1 tumor-bearing mice. * p < 0.05; ** p < 0.01; **** p < 0.0001 compared with αCD137-PBNP-PTT group. Copyright 2024 [166], Taylor & Francis. G) The construction of MPB-3BP@CM NPs and their implementation in combined therapy for CRC. Copyright 2024 [171], Nature